A股收評:三大指數小幅上漲,光刻機、創新藥板塊走高
A股主要指數今日低開高走,午後收窄漲幅;截至收盤,滬指漲0.15%報3373點,深證成指漲0.23%,創業板指漲0.24%。全天成交1.22萬億元,較前一交易日增量366億元,全市場超3300股下跌。盤面上,光刻機概念爆發,新萊應材等近10股漲停;2024年中國創新藥市場規模超過1.13萬億元,創新藥板塊走高,華東醫藥等多股漲停;化工板塊走強,中毅達等多股漲停;CRO板塊拉昇,陽光諾和漲超8%;電子化學品、減肥藥及寵物經濟等板塊漲幅居前。另外,超導概念下挫,永鼎股份逼近跌停;海工裝備板塊大跌,寶色股份等多股跌超10%;風電板塊走低,天能重工跌超9%;輪轂電機、海洋經濟及可控核聚變等板塊跌幅居前。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.